AGIO AGIOS PHARMACEUTICALS, INC.
P/E
--
Forward P/E
2.466
Price/Sales
22.57
Beta
0.63
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Agios Pharmaceuticals' third quarter 2026 revenue of $55M beat estimates behind strong thalassemia drug launch
Agios Pharmaceuticals reported a substantial revenue beat for the third quarter of 2026, primarily driven by the accelerated U.S. commercial adoption of...
Agios Pharm Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Agios Pharmaceuticals is expected to report Q3 2026 revenue of $9.11 million and a loss per share of $1.32, with its current $46.60 share price trading...